

This listing of claims will replace all prior versions, and listings, of claims in the application:

AMENDMENTS TO THE CLAIMS

B1 1-12 (Canceled)

13. (Currently Amended) A therapeutic or preventive method for cerebrovascular disorders comprising introducing HGF gene and/or a VEGF gene in the form of HJV-liposomes by direct injection into the subarachnoid space in humans thereby treating or preventing said cerebrovascular disorders.

14. (Currently Amended) A therapeutic or preventive method for reduced blood flow comprising introducing an HGF gene and/or a VEGF gene in the form of HJV-liposomes by direct injection into the subarachnoid space in humans thereby treating or preventing said reduced blood flow.

15. (Currently Amended) A method of promoting cerebral angiogenesis comprising introducing an HGF gene and/or VEGF gene in the form of HJV-liposomes by direct injection into the subarachnoid space in humans thereby promoting said cerebral angiogenesis.

16. (Currently Amended) A method of suppressing neuronal death in the brain comprising introducing an HGF gene in the form of HJV-liposomes by direct injection into the subarachnoid space in humans thereby suppressing said neuronal death in the brain.

17. (Currently Amended) A method of suppressing apoptosis of nerve cells in the brain comprising introducing by direct injection an HGF gene in the form of HJV-liposomes into the subarachnoid space in humans thereby suppressing said apoptosis of nerve cells.

B¹
18-25. (Canceled)
